Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
EMMPRIN/CD147 Antibody (BSG/963), Novus Biologicals™

Mouse Monoclonal Antibody
Supplier: Novus Biologicals NBP2445370.02MG
Description
Ensure accurate, reproducible results in Flow Cytometry, Immunohistochemistry (Paraffin), Immunofluorescence
EMMPRIN/CD147 Monoclonal specifically detects EMMPRIN/CD147 in Human samples. It is validated for Immunohistochemistry, Immunohistochemistry-Paraffin.Specifications
EMMPRIN/CD147 | |
Monoclonal | |
0.2mg/mL | |
Flow Cytometry 0.5 - 1 ug/million cells in 0.1 ml, Immunohistochemistry-Paraffin 0.5 - 1.0 ug/ml, Immunofluorescence 1:100-1:200 | |
5F7, basigin, basigin (Ok blood group), CD147, CD147 antigen, Collagenase stimulatory factor, EMMPRINTCSF, Extracellular matrix metalloproteinase inducer, Leukocyte activation antigen M6, M6, OK, OK blood group antigen, Tumor cell-derived collagenase stimulatory factor | |
Mouse | |
Protein A or G purified | |
RUO | |
Primary | |
This MAb recognizes extracellular epitope of human CD147. It is expressed more intensely on thymocytes than on mature peripheral blood T cells. CD147 is important in spermatogenesis, embryo implantation, neural network formation, and tumor progression. It stimulates the production of interstitial collagenase, gelatinase A, stromelysin-1 and various metalloproteinases (MMPs) by fibroblasts. These enzymes are important factors in cancer invasion and metastasis. | |
Store at 4C. | |
IgG1 |
Flow Cytometry, Immunohistochemistry (Paraffin), Immunofluorescence | |
BSG/963 | |
Unconjugated | |
10mM PBS and 0.05% BSA with 0.05% Sodium Azide | |
BSG | |
Recombinant human BSG protein | |
0.02 mg | |
Cancer, Signal Transduction, Vision | |
682 | |
Human | |
Purified |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
For Research Use Only
Spot an opportunity for improvement?Share a Content Correction